Last reviewed · How we verify

salvianolate injection

Green Valley Group of China · FDA-approved active Small molecule

Salvianolate is a water-soluble extract from Salvia miltiorrhiza that improves microcirculation and reduces blood viscosity by inhibiting platelet aggregation and promoting fibrinolysis.

Salvianolate is a water-soluble extract from Salvia miltiorrhiza that improves microcirculation and reduces blood viscosity by inhibiting platelet aggregation and promoting fibrinolysis. Used for Acute ischemic stroke, Unstable angina pectoris, Myocardial infarction.

At a glance

Generic namesalvianolate injection
Also known asSalvianolate
SponsorGreen Valley Group of China
Drug classHerbal extract / antiplatelet agent
ModalitySmall molecule
Therapeutic areaCardiovascular / Cerebrovascular
PhaseFDA-approved

Mechanism of action

Salvianolate contains multiple active compounds (salvianolic acids) that work through antiplatelet and anticoagulant mechanisms to enhance blood flow and reduce thrombotic events. It is believed to act on multiple pathways including inhibition of thromboxane synthesis and enhancement of prostacyclin, thereby improving tissue perfusion and reducing ischemic injury in cardiovascular and cerebrovascular conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: